

August 11, 2023

**To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001**

**To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051**

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Outcome of the Board Meeting held on 11th August, 2023

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company at its meeting held today, has approved the re-appointment of Ms. Sona Saira Ramasastry (DIN- 08398547) as Non-Executive Independent Director of the Company for a further period of 5 years with effect from 01st April, 2024. The said re-appointment is subject to shareholder's approval at the ensuing Annual General Meeting.

Further, this is to confirm that Ms. Sona Saira Ramasastry, Non- Executive Independent Director of the Company is not debarred from holding the office pursuant to any SEBI order or any such authority respectively.

The details pertaining to re-appointment of Ms. Sona Saira Ramasastry, in terms of SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is enclosed as Annexure I.

You are requested to take the same on record.

Thanking You.
Yours faithfully,
For Glenmark Pharmaceuticals Limited

**Harish Kuber
Company Secretary & Compliance Officer**

Encl: As above

Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure I

Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015

Sr. No.	Particulars	Details
1.	Name & Designation of Director	Ms. Sona Saira Ramasastry (Non-Executive Independent Director)
2.	Reason for change	Re-appointment
3.	Date of appointment & term of appointment	Effective date of re-appointment - From 1st April, 2024 for a further period of 5 years
4.	Brief Profile	Ms. Ramasastry is a Non-Executive Independent Director at Glenmark Pharmaceuticals Limited since 01st April, 2019. She has over two decades of experience in the Life Sciences industry, successfully building companies as an advisor, board member and operational executive. Ms. Ramasastry is the Founder and Managing Partner of Life Sciences Advisory, LLC. She serves on the board of directors of several public biopharmaceutical companies. Ms. Ramasastry is also a health innovator fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.
5.	Disclosure of relationships between directors (in case of appointment of a director)	None

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com